Efficacy and safety of empagliflozin according to background diuretic use in HFrEF: post-hoc analysis of EMPEROR-reduced
Background - The EMPEROR-Reduced (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction) trial established the efficacy of empagliflozin in reducing heart failure (HF) outcomes among patients with heart failure with reduced ejection fraction (HFrEF). - Obj...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2024
|
| In: |
JACC Heart failure
Year: 2024, Jahrgang: 12, Heft: 1, Pages: 35-46 |
| ISSN: | 2213-1787 |
| DOI: | 10.1016/j.jchf.2023.06.036 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.jchf.2023.06.036 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2213177923004535 
|
| Verfasserangaben: | Nitish K. Dhingra, MD, Subodh Verma, MD, PHD, Javed Butler, MD, MPH, MBA, Stefan D. Anker, MD, PHD, Joao Pedro Ferreira, MD, Gerasimos Filippatos, MD, James L. Januzzi, MD, Carolyn S.P. Lam, PHD, MBBS, Naveed Sattar, MD, Liliana Zaremba-Pechmann, PHD, Michael Böhm, MD, Matias Nordaby, MD, Martina Brueckmann, MD, Stuart J. Pocock, PHD, Faiez Zannad, MD, PHD, Milton Packer, MD, on behalf of the EMPEROR-Reduced Trial Committees and Investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1892774410 | ||
| 003 | DE-627 | ||
| 005 | 20241205145344.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240701s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jchf.2023.06.036 |2 doi | |
| 035 | |a (DE-627)1892774410 | ||
| 035 | |a (DE-599)KXP1892774410 | ||
| 035 | |a (OCoLC)1475301135 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dhingra, Nitish |e VerfasserIn |0 (DE-588)1334504148 |0 (DE-627)1892775514 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of empagliflozin according to background diuretic use in HFrEF |b post-hoc analysis of EMPEROR-reduced |c Nitish K. Dhingra, MD, Subodh Verma, MD, PHD, Javed Butler, MD, MPH, MBA, Stefan D. Anker, MD, PHD, Joao Pedro Ferreira, MD, Gerasimos Filippatos, MD, James L. Januzzi, MD, Carolyn S.P. Lam, PHD, MBBS, Naveed Sattar, MD, Liliana Zaremba-Pechmann, PHD, Michael Böhm, MD, Matias Nordaby, MD, Martina Brueckmann, MD, Stuart J. Pocock, PHD, Faiez Zannad, MD, PHD, Milton Packer, MD, on behalf of the EMPEROR-Reduced Trial Committees and Investigators |
| 264 | 1 | |c January 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 13. September 2023, Artikelversion: 2. Januar 2024 | ||
| 500 | |a Gesehen am 01.07.2024 | ||
| 520 | |a Background - The EMPEROR-Reduced (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction) trial established the efficacy of empagliflozin in reducing heart failure (HF) outcomes among patients with heart failure with reduced ejection fraction (HFrEF). - Objectives - The authors examined the outcomes of EMPEROR-Reduced as a function of background diuretic therapy. - Methods - The EMPEROR-Reduced trial was a double-blind, randomized controlled trial of placebo vs empagliflozin 10 mg among 3,730 HFrEF patients. Herein, the population was stratified into 4 groups: no diuretic and diuretic dose equivalent to furosemide <40, 40, and >40 mg daily at baseline. - Results - A total of 3,656 patients from the EMPEROR-Reduced trial were available for analysis. Of those patients, 482 (13.2%) were receiving no diuretic therapy, and 731 (20.0%), 1,411 (38.6%), and 1,032 (28.2%) were receiving <40 mg, 40 mg, and >40 mg, respectively. The efficacy of empagliflozin on the primary outcome (time to first event of hospitalization for HF or cardiovascular [CV] death) was consistent regardless of background diuretic therapy (>40 mg: HR: 0.88 [95% CI: 0.71-1.10]; 40 mg: HR: 0.65 [95% CI: 0.51-0.82]; <40 mg: HR: 0.65 [95% CI: 0.46-0.92]); no diuretic agents: HR: 0.78 [95% CI: 0.47-1.29]; Ptrend test = 0.192). Baseline diuretic doses did not influence the effect of empagliflozin on body weight, systolic blood pressure, NT-proBNP, or hematocrit at 52 weeks. The safety profile of empagliflozin vs placebo was unaffected by baseline diuretic dose; however, independently of treatment allocation, total rates of adverse events were higher among patients with higher baseline doses of diuretic agents. - Conclusions - Empagliflozin exhibits a consistent effect on time to CV death or HF hospitalization and an unaltered safety profile regardless of baseline diuretic therapy. | ||
| 650 | 4 | |a diuretic agents | |
| 650 | 4 | |a empagliflozin | |
| 650 | 4 | |a heart failure with reduced ejection fraction | |
| 700 | 1 | |a Verma, Subodh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Butler, Javed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anker, Stefan D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferreira, Joao Pedro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Januzzi, James L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lam, Carolyn S. P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sattar, Naveed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zaremba-Pechmann, Liliana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Böhm, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nordaby, Matias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Pocock, Stuart J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zannad, Faiez |e VerfasserIn |4 aut | |
| 700 | 1 | |a Packer, Milton |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a American College of Cardiology |t JACC Heart failure |d Amsterdam [u.a.] : Elsevier, 2013 |g 12(2024), 1 vom: Jan., Seite 35-46 |h Online-Ressource |w (DE-627)73770232X |w (DE-600)2705621-1 |w (DE-576)379733455 |x 2213-1787 |7 nnas |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:1 |g month:01 |g pages:35-46 |g extent:12 |a Efficacy and safety of empagliflozin according to background diuretic use in HFrEF post-hoc analysis of EMPEROR-reduced |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jchf.2023.06.036 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2213177923004535 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240701 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 13 | ||
| 999 | |a KXP-PPN1892774410 |e 4544558700 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1892774410","id":{"eki":["1892774410"],"doi":["10.1016/j.jchf.2023.06.036"]},"language":["eng"],"physDesc":[{"noteIll":"Illustrationen","extent":"12 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Online verfügbar: 13. September 2023, Artikelversion: 2. Januar 2024","Gesehen am 01.07.2024"],"person":[{"role":"aut","given":"Nitish","display":"Dhingra, Nitish","family":"Dhingra","roleDisplay":"VerfasserIn"},{"given":"Subodh","role":"aut","roleDisplay":"VerfasserIn","family":"Verma","display":"Verma, Subodh"},{"role":"aut","given":"Javed","roleDisplay":"VerfasserIn","family":"Butler","display":"Butler, Javed"},{"roleDisplay":"VerfasserIn","display":"Anker, Stefan D.","family":"Anker","given":"Stefan D.","role":"aut"},{"role":"aut","given":"Joao Pedro","display":"Ferreira, Joao Pedro","family":"Ferreira","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Filippatos","display":"Filippatos, Gerasimos","given":"Gerasimos","role":"aut"},{"role":"aut","given":"James L.","roleDisplay":"VerfasserIn","family":"Januzzi","display":"Januzzi, James L."},{"roleDisplay":"VerfasserIn","display":"Lam, Carolyn S. P.","family":"Lam","given":"Carolyn S. P.","role":"aut"},{"display":"Sattar, Naveed","family":"Sattar","roleDisplay":"VerfasserIn","given":"Naveed","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Zaremba-Pechmann","display":"Zaremba-Pechmann, Liliana","role":"aut","given":"Liliana"},{"role":"aut","given":"Michael","display":"Böhm, Michael","family":"Böhm","roleDisplay":"VerfasserIn"},{"given":"Matias","role":"aut","roleDisplay":"VerfasserIn","display":"Nordaby, Matias","family":"Nordaby"},{"role":"aut","given":"Martina","family":"Brückmann","display":"Brückmann, Martina","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Stuart J.","roleDisplay":"VerfasserIn","display":"Pocock, Stuart J.","family":"Pocock"},{"given":"Faiez","role":"aut","display":"Zannad, Faiez","family":"Zannad","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Packer","display":"Packer, Milton","given":"Milton","role":"aut"}],"title":[{"title":"Efficacy and safety of empagliflozin according to background diuretic use in HFrEF","subtitle":"post-hoc analysis of EMPEROR-reduced","title_sort":"Efficacy and safety of empagliflozin according to background diuretic use in HFrEF"}],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"January 2024"}],"name":{"displayForm":["Nitish K. Dhingra, MD, Subodh Verma, MD, PHD, Javed Butler, MD, MPH, MBA, Stefan D. Anker, MD, PHD, Joao Pedro Ferreira, MD, Gerasimos Filippatos, MD, James L. Januzzi, MD, Carolyn S.P. Lam, PHD, MBBS, Naveed Sattar, MD, Liliana Zaremba-Pechmann, PHD, Michael Böhm, MD, Matias Nordaby, MD, Martina Brueckmann, MD, Stuart J. Pocock, PHD, Faiez Zannad, MD, PHD, Milton Packer, MD, on behalf of the EMPEROR-Reduced Trial Committees and Investigators"]},"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 10.09.2025"],"title":[{"title_sort":"JACC Heart failure","subtitle":"a journal of the American College of Cardiology","title":"JACC Heart failure"}],"recId":"73770232X","language":["eng"],"id":{"zdb":["2705621-1"],"issn":["2213-1787"],"eki":["73770232X"]},"physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2024","text":"12(2024), 1 vom: Jan., Seite 35-46","issue":"1","extent":"12","volume":"12","pages":"35-46"},"corporate":[{"role":"aut","display":"American College of Cardiology","roleDisplay":"VerfasserIn"}],"origin":[{"dateIssuedKey":"2013","publisherPlace":"Amsterdam [u.a.] ; New York, NY","publisher":"Elsevier ; American College of Cardiology Foundation","dateIssuedDisp":"2013-"}],"disp":"American College of CardiologyJACC Heart failure","pubHistory":["1.2013 -"]}]} | ||
| SRT | |a DHINGRANITEFFICACYAN2024 | ||